B7-H3-CAR T cells (St. Jude)

B7-H3-CAR T cells is an investigational autologous chimeric antigen receptor (CAR) T-cell therapy developed by St. Jude Children's Research Hospital for the treatment of pediatric patients with relapsed or refractory B7-H3-positive sarcomas. The therapy involves genetically engineering a patient's own T cells to express a CAR targeting B7-H3 (CD276), a checkpoint molecule that is highly expressed on various pediatric solid tumors, including osteosarcoma, rhabdomyosarcoma, and Ewing sarcoma, while maintaining limited expression in normal tissues. The specific CAR construct utilizes a single-chain variable fragment (scFv) derived from the MGA271 (enoblituzumab) antibody and incorporates both CD28 and 4-1BB costimulatory domains to enhance T-cell activation, metabolic fitness, and long-term persistence. In clinical trials, such as the RAD3CAR study, the therapy is evaluated in combination with hypofractionated radiation therapy and lymphodepleting chemotherapy (fludarabine and cyclophosphamide) to potentially improve CAR T-cell trafficking and overcome the immunosuppressive tumor microenvironment.

Other names

B7-H3-specific chimeric antigen receptor T cellsB-7-H3-specific chimeric antigen receptor T cellsB 7-H3-specific chimeric antigen receptor T cellsCD276-targeted CAR T cellsCD-276-targeted CAR T cellsCD 276-targeted CAR T cellsB7-H3 CAR-TB-7-H3 CAR-TB 7-H3 CAR-T